CONTENTS

Chapter 1  Introduction:
1. General introduction.  8
2. History of the disease ankylosing spondylitis.  11
3. History of therapy in ankylosing spondylitis.  21
4. Objectives and outline of this thesis.  29

Chapter 2  Efficacy and safety of mesalazine (Salofalk®) in an open study of 20 patients with ankylosing spondylitis.  41

Chapter 3  Statin therapy might be beneficial for treating patients with ankylosing spondylitis.  51

Chapter 4  Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis.  57

Chapter 5  Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.  71

Chapter 6  Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept.  81

Chapter 7  What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function.  95

Chapter 8  Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis.  107

Chapter 9  Etanercept increases bone mineral density in ankylosing spondylitis, but does not prevent the increase of vertebral fractures.  121

Chapter 10  1. General discussion and summary.  138
2. Nederlandse samenvatting.  162
3. Dankwoord.  168
4. Curriculum vitae.  169
5. List of publications.  170
6. List of abbreviations and illustrations.  173